In February 2026, Kenya received its first shipment of 21,000 doses of lenacapavir, a long-acting injectable requiring only two shots a year, marking a major step forward in HIV prevention in Kenya. The drug recorded more than 96% effectiveness at preventing HIV in clinical trials, one of the most significant advances in global health since daily oral medication became the standard prevention tool.

HIV and Poverty in Kenya

Nearly 45.5% of Kenyans live below the international poverty line of $3 a day, according to the World Bank. For low-income communities, HIV carries consequences that extend well beyond health. At the household level, the cost of care depletes savings, reduces economic productivity and can trap families in cycles of intergenerational poverty. Preventing new infections is therefore not only a public health priority, it is an economic one.

Why a Twice-Yearly Shot Matters

For years, the primary tool for preventing HIV in people at high risk had been oral pre-exposure prophylaxis, or PrEP, a pill that must be taken every day. Consistent use is a genuine challenge for many people, particularly in communities where irregular health care access and demanding daily routines make routine medication difficult to maintain. In many communities, carrying daily HIV medication can lead others to assume a person is HIV-positive, a stigma that drives some people to stop taking the pill altogether.

Lenacapavir addresses this challenge directly. A single injection provides six months of protection, removing the need for daily pills. The World Health Organization endorsed the drug in July 2025, making it the first twice-yearly injectable PrEP option to be officially recommended for global use.

Kenya’s Rollout: Fast and Phased

Kenya’s Pharmacy and Poisons Board completed its regulatory review and registered lenacapavir for national use in January 2026. The first consignment of 21,000 doses arrived in Nairobi on Feb. 17, 2026, delivered through a partnership between the Ministry of Health and the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund coordinated procurement and negotiated access pricing, while the Ministry of Health managed regulatory approval and national distribution strategy. An additional 12,000 doses followed in April, and the U.S. government pledged a further 25,000 to support early implementation.

The Ministry of Health launched Phase 1 in March 2026, targeting 152 health facilities across 15 high-burden counties, with an estimated 58,000 individuals expected to receive the injection in the first phase alone. Two additional phases are planned, with the aim of reaching nationwide coverage by 2027. Health officials say this milestone reflects the country’s readiness to integrate modern prevention tools through its Universal Health Coverage framework.

Making It Affordable

Cost has historically been one of the biggest barriers to equitable HIV prevention in Kenya and across sub-Saharan Africa. Lenacapavir carries a global list price exceeding $42,000 per patient per year, but the Ministry of Health is offering it free of charge at selected public health facilities. For the health system, the estimated annual cost is approximately $60 per patient. This dramatic price reduction was made possible through licensing agreements and Global Fund procurement support.

Peter Sands, executive director of the Global Fund, described the moment as one requiring urgency and ambition. “Long-acting lenacapavir could reshape HIV prevention by overcoming the structural challenges that have long constrained uptake,” Sands said. He added that the task is now to translate scientific progress into rapid, broad and equitable access.

The Road Ahead

Kenya has approximately 1.4 million people living with HIV. The national rollout directly supports prevention of mother-to-child transmission, a stated priority of the Ministry of Health, with the overarching goal of ensuring every child born in Kenya is HIV-free.

Generic versions of lenacapavir are expected to reach markets by 2027 at an estimated yearly cost of $40 per person. This development could open access far beyond Kenya’s borders. The phased, data-driven structure of Kenya’s rollout has positioned the country as a model for how HIV prevention can evolve to be accessible and equitable and for how protecting public health and reducing poverty can go hand in hand.

– Gonzalo Rodriguez Da Fonte Martins

Gonzalo is based in London, UK and focuses on Global Health for The Borgen Project.

Photo: Pexels